News & Updates

Pulsed field ablation (PFA) was noninferior to cryoballoon ablation (CBA) in preventing atrial tachyarrhythmia recurrence among patients with symptomatic paroxysmal atrial fibrillation (AF), according to the SINGLE SHOT CHAMPION trial presented at EHRA 2025.

A recent trial presented at ACC.25 has demonstrated the efficacy of AZD0780 in reducing low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, with a favourable safety and tolerability profile.

Once-daily treatment with oral semaglutide, a GLP-1* receptor agonist, significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), according to the SOUL** trial presented at ACC.25.

Resumption of direct oral anticoagulants (DOACs) a day after undergoing colorectal endoscopic submucosal dissection (ESD) results in fewer thromboembolic events without elevating the risk of delayed bleeding compared with 2 or 3 days after ESD, reports a study.

Exposure to pharmacological treatments for attention-deficit hyperactivity disorder (ADHD) appears to confer increases in blood pressure and pulse among children, teens, and adults, according to the results of a meta-analysis.

In the long-term maintenance period after percutaneous coronary intervention (PCI), monotherapy with clopidogrel appears to work better than aspirin at preventing major adverse cardiac and cerebrovascular events in Asian patients at high risk of recurrent ischaemic events, as shown in the open-label SMART-CHOICE 3 trial conducted in South Korea.

Elderly patients with aortic stenosis who received dapagliflozin after transcatheter aortic-valve implantation (TAVI) had better outcomes than those who did not receive the drug, according to the DapaTAVI* trial presented at ACC.25.